LBP SA01
Alternative Names: LBP-SA01Latest Information Update: 01 Mar 2024
At a glance
- Originator Locus Biosciences
- Class Antibacterials; Bacteriophages; Gene therapies
- Mechanism of Action Bacterial DNA degraders; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Staphylococcal infections
Most Recent Events
- 23 Feb 2024 Preclinical trials in Staphylococcal infections in USA (unspecified route) prior to February 2024 (Locus Biosciences pipeline, February 2024)